Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
08 nov. 2023 07h00 HE
|
Avadel Pharmaceuticals plc
-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
07 nov. 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8
30 oct. 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
20 oct. 2023 08h00 HE
|
Avadel Pharmaceuticals plc
– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October...
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
05 oct. 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
31 août 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
09 août 2023 07h00 HE
|
Avadel Pharmaceuticals plc
-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 août 2023 16h05 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
02 août 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 juil. 2023 16h05 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...